News Bluebird bio details plans to file three blockbusters Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
News Celgene in talks to buy CAR-T partner Juno Celgene is understood to be in talks to buy CAR-T specialists Juno Therapeutics, in a deal which could be worth around $7 billion.
News Cellectis gets FDA go-ahead to restart fatal CAR-T trial Regulator agrees to restart phase 1 trial of UCART 123
News Kite in CAR-T pole position as rolling submission begins Kite to start filing data for KTE-C19 with US regulator.
News In shock move, EU panel rejects Alzheimer's drug Leqembi The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.